<DOC>
	<DOCNO>NCT01183663</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dos combination lenalidomide drug give patient advanced cancer . The safety drug combination also study .</brief_summary>
	<brief_title>Lenalidomide Combination With Bevacizumab , Sorafenib , Temsirolimus , 5-Fluorouracil , Leucovorin , Oxaliplatin ( FOLFOX )</brief_title>
	<detailed_description>The Study Drugs : Lenalidomide design change body 's immune system . It may also interfere development tiny blood vessel help support tumor growth . This may decrease prevent growth cancer cell . Bevacizumab design block growth blood vessel supply nutrient need tumor growth . This may prevent slow growth cancer cell . Bevacizumab long FDA approve treat breast cancer . Sorafenib design block function important protein cancer cell . These protein , active , part responsible abnormal growth behavior cancer cell . Temsirolimus design block growth cancer cell , may cause cancer cell die . FOLFOX ( 5-fluorouracil , leucovorin , oxaliplatin ) drug combination design kill rapidly divide cell stop DNA ( genetic material cell ) duplicating . Because pharmacy shortage IV leucovorin , patient continue treatment without leucovorin becomes available . Study Groups ( Arms ) : If find eligible take part study , assign 1 4 study arm . Each study arm receive lenalidomide combination 1 4 drugs/drug combination describe `` Study Drugs '' section . The arm assign depend arm still open doctor think appropriate . Your doctor consider type disease , drug receive disease , side effect may see drug decide arm assign : - If Arm 1 , receive lenalidomide bevacizumab . - If Arm 2 , receive lenalidomide sorafenib . - If Arm 3 , receive lenalidomide temsirolimus . - If Arm 4 , receive lenalidomide FOLFOX . Up 4 dose level drug combination test arm . Up 6 participant enrol dose level arm . For arm , first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose drug combination find arm . After high tolerable dose drug combination find , additional 20 patient able receive combination dose arm . Study Drug Administration : If Arm 1 , 2 , 3 , study `` cycle '' 28 day . If Arm 4 , study cycle 21 day . If Arms 1 , 2 , 3 , take lenalidomide mouth 1 time day Days 1-21 study cycle . If Arm 4 , take lenalidomide mouth 1 time day Days 1-14 study cycle . Swallow lenalidomide capsule whole 1 cup ( 8 ounce ) water . Do break , chew , open capsule . If miss dose lenalidomide , take soon remember day . If miss take dose entire day , take regular dose next schedule day ( NOT take double regular dose make miss dose ) . If take prescribe dose lenalidomide , seek emergency medical care need contact study staff right away . Women able become pregnant might care touch lenalidomide capsule bottle unless wear glove . Any unused Revlimid速 ( lenalidomide ) return instructed RevAssist速 program . Arm 1 : You receive bevacizumab vein Days 1 15 cycle . The first time receive bevacizumab , give 90 minute . If tolerate well , rest dos give 30-60 minute . Arm 2 : You take sorafenib mouth 1 time day every cycle ( Days 1-28 ) . You take cup ( 8 ounce ) water , take lenalidomide . You eat drink anything water least 1 hour take sorafenib . Arm 3 : You receive temsirolimus vein 30-60 minute Days 1 , 8 , 15 , 22 cycle . Arm 4 : You receive oxaliplatin leucovorin vein 2 hour Day 1 cycle . You also receive 5-FU vein 22 hour home Days 1-2 . The drug give pump carry . Study Visits : At study visit , ask side effect may drug may receive . On Day 1 Cycle 1 , follow test procedure perform perform within 7 day Day 1 Cycle 1 : - You physical exam , include measurement weight vital sign . - Your performance status record . - Blood ( 1 tablespoon ) drawn routine test . On Day 15 Cycle 1 , blood ( 1 tablespoon ) drawn routine test . On Day 1 every even numbered cycle ( Cycles 2 , 4 , 6 , ) : - You physical exam , include measurement weight vital sign . - Your performance status record . - Blood ( 1 tablespoon ) drawn routine test . At end every even numbered cycle ( Day 28 Arms 1 , 2 , 3 ; Day 21 Arm 4 ) : - You CT scan , MRI scan , positron emission compute tomograph ( PET ) scan , PET/CT scan check status disease . If study doctor think best interest , type scan list may also perform . The study doctor explain type scan detail , may ask sign separate consent form describe scan risk detail . - If study doctor think need , either CT MRI scan brain check status disease . - Blood ( 1 tablespoon ) drawn tumor marker . On Day 1 every odd number cycle ( Cycles 3 , 5 , 7 , ) : - You physical exam , include measurement weight vital sign . - Your performance status record . - Blood ( 1 tablespoon ) drawn routine test . Pregnancy Testing : If woman able become pregnant , blood ( 1 teaspoon ) urine pregnancy test Day 1 every cycle , 1 time week first cycle , stop take study drug , 30 day stop take study drug . Length Study : You may continue take study drug long doctor think best interest . You longer able take study drug disease get bad intolerable side effect occur . Follow-Up Visit : Thirty ( 30 ) day stop take study drug reason , follow test procedure perform : - You physical exam , include measurement weight vital sign . - Your performance status record . - Blood ( 2 tablespoon ) draw routine test tumor marker test . - You ECG . - You CT scan , MRI scan , PET scan , PET/CT scan check status disease . If study doctor think best interest , type scan list may also perform . The study doctor explain type scan detail , may ask sign separate consent form describe scan risk detail . - If study doctor think need , either CT MRI scan brain check status disease . This investigational study . All study drug FDA-approved commercially available use various type cancer : - Lenalidomide : multiple myeloma myelodysplastic syndrome - Bevacizumab : colorectal lung cancer - Sorafenib : liver carcinoma renal cell carcinoma - Temsirolimus : renal cell carcinoma - 5-FU : cancer breast , pancreas , colon/rectum , stomach , type skin cancer ( superficial basal cell carcinoma ) - Oxaliplatin leucovorin : colorectal cancer It investigational give lenalidomide combination drug patient advance cancer . Up 180 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients advance metastatic cancer refractory standard therapy , relapse standard therapy , standard therapy available . 2 . Patients must &gt; /= 3 week beyond treatment cytotoxic chemotherapy regimen , therapeutic radiation , major surgery . After targeted biologic therapy 5 halflives three week , whichever short . Patients may receive palliative localize radiation immediately treatment , provide radiation deliver site disease treat protocol . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 4 . Patients must normal organ marrow function , define absolute neutrophil count &gt; /= 1,000/mL ; platelet &gt; /=50,000/mL ( unless abnormality due bone marrow involvement ) ; creatinine clearance &gt; /= 50 ml/min CockcroftGault formula ; total bilirubin &lt; /= 2.0 ; alanine aminotransferase ( ALT ) / serum glutamic pyruvic transaminase ( SGPT ) &lt; /= 5 X upper limit normal ( ULN ) ( unless patient liver metastasis ) . 5 . All study participant must register mandatory RevAssist速 program , willing able comply requirement RevAssist速 . 6 . Females childbearing potential ( FCBP ) must negative serum urine pregnancy test sensitivity least 50 milliInternational unit ( mIU ) /mL within 10 14 day prior within 24 hour prescribe lenalidomide ( prescription must fill within 7 day ) must either commit continued abstinence intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 28 day start take lenalidomide . FCBP must also agree ongoing pregnancy test . Men must agree use latex condom sexual contact FCBP even successful vasectomy . 7 . Patients must able understand willing sign write informed consent document . 8 . Must &gt; /= 18 year age . 1 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . 2 . Uncontrolled intercurrent illness , include , limited , uncontrolled infection , uncontrolled asthma , need hemodialysis , need ventilatory support . 3 . Pregnant breast feeding female . ( Lactating female must agree breast feed take lenalidomide ) . 4 . Use experimental drug therapy within 21 day baseline . 5 . Known hypersensitivity thalidomide . 6 . History hypersensitivity component formulation . 7 . The development erythema nodosum , characterize desquamate rash take thalidomide similar drug . 8 . Patients unwilling unable sign inform consent document . 9 . Uncontrolled systemic vascular hypertension ( Systolic blood pressure &gt; 140 mmHg , diastolic blood pressure &gt; 90 mmHg medication ) patient treat bevacizumab sorafenib arm . 10 . Patients active deep venous thrombosis pulmonary embolism patient receive anticoagulation . 11 . Patients clinically significant cardiovascular disease : History cerebrovascular accident ( CVA ) within 6 month ; Myocardial infarction unstable angina within 6 month ; Unstable angina pectoris . 12 . Uncontrolled intercurrent illness , include , limited , ongoing active infection require parenteral antibiotic Day 1 . 13 . Major surgical procedure , open biopsy significant traumatic injury within 28 day prior Day 0 protocol treatment . 14 . Patients take CYP3A4 inducer and/or inhibitor , consider temsirolimus arm : If patient history take CYP3A4 inducer and/or inhibitor prior enrollment temsirolimus arm , strongly recommend patient stop drug wait least 5 halflives say drug initiate therapy temsirolimus arm .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Lenalidomide</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Temsirolimus</keyword>
	<keyword>5-Fluorouracil</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Avastin</keyword>
	<keyword>Anti-VEGF monoclonal antibody</keyword>
	<keyword>rhuMAB-VEGF</keyword>
	<keyword>CC-5013</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Nexavar</keyword>
	<keyword>BAY 43-90006</keyword>
	<keyword>Metastatic cancer</keyword>
	<keyword>Metastatic colorectal cancer</keyword>
	<keyword>Advanced solid tumor</keyword>
	<keyword>Hematologic malignancy</keyword>
	<keyword>Colon cancer</keyword>
	<keyword>Advanced colorectal cancer</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Pancreatic cancer</keyword>
	<keyword>Gastric cancer</keyword>
	<keyword>Advanced renal cell carcinoma</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Unresectable hepatocellular carcinoma</keyword>
	<keyword>Renal cell carcinoma</keyword>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Multiple myeloma</keyword>
</DOC>